Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Buys Renal Disease Biotech Fibrotech, Aims Big At Neuroscience

This article was originally published in The Pink Sheet Daily

Executive Summary

The Ireland-based specialty pharma, itself created by acquisition, generated strong top-line revenue growth and higher profits in the first quarter, helped by full consolidation of ViroPharma. Shire also underscored its aim for future innovation by buying renal disease biotech Fibrotech and predicting its neuroscience operations will double sales by 2020.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel